Gritstone bio, Inc.
https://gritstonebio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Gritstone bio, Inc.
From Treatment To Prevention To A Cure: An Interview With Gilead’s HIV R&D Leaders
Gilead execs Jared Baeten and Tomas Cihlar talk to Scrip about how the company, still the leader in HIV, is working toward less-frequent dosing, providing PrEP for broader populations and maybe finding a cure for HIV infection.
Finance Watch: Public Market Opens Up Enough To Let An IPO Through
Public Company Edition: MAIA launches a $10m initial public offering, the first in the US since May, but NewAmsterdam opts for the SPAC route to the stock market. Also, Legend raises $350m in a follow-on offering, Iveric obtains access to $250m in debt and Otonomy cuts costs after a Phase II failure.
The BioPharma Shares Rising On Omicron Hopes And Fears
Adagio Therapeutics and Gritstone bio are two companies who could add to the armamentarium against Omicron.
AstraZeneca Moves Into Self-Amplifying RNA With VaxEquity Deal
VaxEquity’s founder dropped out of the race to develop a COVID-19 vaccine last year – but it and new partner AstraZeneca see potential not just in vaccines, but therapeutics too.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Digital Health
- Artificial Intelligence
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Gritstone Oncology, Inc.